Literature DB >> 10857902

Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide.

Y Z Patt1, M M Hassan, R D Lozano, L M Ellis, J A Peterson, K A Waugh.   

Abstract

Thalidomide, a sedative agent previously associated with severe fetal malformations, has anti-angiogenic activity. We describe the antitumor effects of thalidomide in a patient with hepatocellular carcinoma that was refractory to systemic and intraarterial therapy.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10857902     DOI： 10.1097/00000421-200006000-00023

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN： 0277-3732            Impact factor:   2.339


  11 in total

Review 1.  Hepatocellular carcinoma: epidemic and treatment.

Authors:  Jill Allen; Alan Venook
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

Review 2.  Anti-angiogenic treatment strategies for malignant brain tumors.

Authors:  M Kirsch; G Schackert; P M Black
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

3.  Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.

Authors:  J B Marriott; I A Clarke; K Dredge; G Muller; D Stirling; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

Review 4.  Thalidomide in cancer treatment: a potential role in the elderly?

Authors:  Shufeng Zhou; Philip Kestell; Malcolm D Tingle; James W Paxton
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

5.  Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice.

Authors:  Zhong-Lin Zhang; Zhi-Su Liu; Quan Sun
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

Review 6.  Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

7.  Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers.

Authors:  Clemens C Cyran; Barbara Sennino; Bundit Chaopathomkul; Yanjun Fu; Victor S Rogut; David M Shames; Michael F Wendland; Donald M McDonald; Robert C Brasch
Journal:  Eur Radiol       Date:  2008-07-30       Impact factor: 5.315

8.  Salvage therapy for hepatocellular carcinoma with thalidomide.

Authors:  Tsang-En Wang; Chin-Roa Kao; Shee-Chan Lin; Wen-Hsiung Chang; Cheng-Hsin Chu; Johson Lin; Ruey-Kuen Hsieh
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

9.  Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts.

Authors:  Wei-Dong Jia; Ge-Liang Xu; Rong-Nan Xu; Hui-Chuan Sun; Lu Wang; Ji-Hai Yu; Jian Wang; Jian-Sheng Li; Zhi-Ming Zhai; Qiong Xue
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-14       Impact factor: 4.553

10.  Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.

Authors:  J B Bartlett; A Michael; I A Clarke; K Dredge; S Nicholson; H Kristeleit; A Polychronis; H Pandha; G W Muller; D I Stirling; J Zeldis; A G Dalgleish
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.